Skip to content
Varubi, Varuby(rolapitant)
Varubi, Varuby (rolapitant) is a small molecule pharmaceutical. Rolapitant was first approved as Varubi on 2015-09-01. It is used to treat nausea and vomiting in the USA. It has been approved in Europe to treat nausea, neoplasms, and vomiting. It is known to target substance-P receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Varubi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rolapitant hydrochloride
Tradename
Company
Number
Date
Products
VARUBITerSera TherapeuticsN-206500 RX2015-09-01
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
varubiNew Drug Application2020-08-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
nauseaHP_0002018D009325R11.0
vomitingHP_0002013D014839R11.1
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Rolapitant Hydrochloride, Varubi, Tersera
91016152032-07-14U-1741
83615002029-10-09DP
84708422029-01-18U-1741
70493202028-08-19DS, DPU-1741
75638012027-04-04DP
79819052027-04-04U-1741
81785502027-04-04DS, DP
84047022027-04-04U-1741
ATC Codes
A: Alimentary tract and metabolism drugs
A04: Antiemetics and antinauseants
A04A: Antiemetics and antinauseants
A04AD: Other antiemetics in atc
A04AD14: Rolapitant
HCPCS
Code
Description
J2797
Injection, rolapitant, 0.5 mg
J8670
Rolapitant, oral, 1 mg
Clinical
Clinical Trials
223 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuromuscular blockadeD01914852172145
AnesthesiaD0007581781127
General anesthesiaD000768372719
Muscle relaxationD009126235110
Postoperative painD010149G89.181337
LaparoscopyD010535426
Muscle weaknessD018908HP_00013241214
Delayed emergence from anesthesiaD055191314
Morbid obesityD009767EFO_0001074224
Rapid sequence induction and intubationD0000796032114
Show 50 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart arrestD006323EFO_0009492I461113
Pancreatic neoplasmsD010190EFO_0003860C2511
Lung neoplasmsD008175C34.90111
Nerve blockD00940711
Back painD001416HP_0003418M5411
Local anesthesiaD00077211
Spinal fusionD01312311
Organophosphate poisoningD062025111
Muscle fatigueD01876311
HypothermiaD007035HP_0002045T6811
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N1911
Out-of-hospital cardiac arrestD05868711
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DeliriumD003693R41.0123
High-frequency jet ventilationD00661111
Spinal fracturesD016103EFO_0003902S1211
Spinal stenosisD013130EFO_0007490M48.011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharyngitisD010612R07.033
Critical illnessD01663822
Patient satisfactionD01706022
Neuromuscular monitoringD06188622
StrabismusD013285HP_0000486H50.211
MelanomaD00854511
Colorectal neoplasmsD01517911
FasciculationD005207R25.311
PneumothoraxD011030J93.1111
BronchoscopyD00199911
Show 20 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameROLAPITANT
INNrolapitant
Description
Rolapitant is an azaspiro compound that is 1,7-diazaspiro[4.5]decan-2-one carrying additional phenyl and 1-{[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl substituents at position 8. Used (in the form of the hydrochloride hydrate) for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It has a role as an antiemetic and a neurokinin-1 receptor antagonist. It is an ether, an azaspiro compound, a member of pyrrolidin-2-ones, a member of piperidines and an organofluorine compound. It is a conjugate base of a rolapitant(1+).
Classification
Small molecule
Drug classtachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Identifiers
PDB
CAS-ID552292-08-7
RxCUI1665496
ChEMBL IDCHEMBL3707331
ChEBI ID
PubChem CID10311306
DrugBankDB09291
UNII IDNLE429IZUC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TACR1
TACR1
Organism
Homo sapiens
Gene name
TACR1
Gene synonyms
NK1R, TAC1R
NCBI Gene ID
Protein name
substance-P receptor
Protein synonyms
neurokinin receptor 1, NK-1 receptor, NK-1R, Tachykinin receptor 1, tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor)
Uniprot ID
Mouse ortholog
Tacr1 (21336)
substance-P receptor (Q8BYR7)
Variants
Clinical Variant
No data
Financial
Varubi - Tesaro
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 231 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,365 adverse events reported
View more details